Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

iPSC-derived MSCs CYP-001

A preparation of allogeneic mesenchymal stem cells (MSCs) derived from induced pluripotent stem cells (iPSCs), with potential immunomodulating activity. iPSCs are derived from one healthy adult donor and are expanded and differentiated into mesenchymoangioblasts (MCAs), which are further expanded and cultured, upon which MSCs are formed and further expanded. Upon intravenous administration and following allogeneic hematopoietic stem cell transplantation (HSCT), the iPSC-derived MSCs CYP-001 may attenuate and prevent acute graft versus host disease (aGvHD).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic MSCs CYP-001
induced pluripotent stem cell-derived mesenchymal stem cells CYP-001
Code name:CYP 001
CYP-001
CYP001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search